Impact of National and International Stem Cell Banking Initiatives on progress in the field of cell therapy: IABS-JST Joint Workshop: Summary for Session 5

Biologicals : Journal of the International Association of Biological Standardization
Takashi Aoi, Glyn N Stacey

Abstract

In order to assure the quality and safety of future advanced cell therapies it is vital to ensure that source materials including the donor cells have been assessed and demonstrated as suitable for use in the development and manufacture of such new medicines. Here we provide a brief overview of the key issues in the delivery of quality controlled and safety tested seed stocks of human pluripotent stem cell lines to support stem cell research and the development of advanced cell therapies. We also reflect on the importance of national and internationally coordinated cell banking systems in this process in order to promote more efficient development of cell therapies.

References

Oct 3, 1999·International Journal of Cancer. Journal International Du Cancer·R A MacLeodH G Drexler
Dec 18, 2009·Stem Cell Reviews and Reports·UNKNOWN International Stem Cell Banking Initiative

❮ Previous
Next ❯

Citations

Jul 14, 2017·Molecular Autism·Jamie ReillySanbing Shen
Feb 15, 2020·Molecular Therapy. Methods & Clinical Development·Vera J MehlerMelanie L Moore

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.